Comparing of Dicerna Pharmaceuticals Inc. (DRNA) and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dicerna Pharmaceuticals Inc. 6.91M 127.40 93.05M -2.23 0.00
Rigel Pharmaceuticals Inc. 44.51M 9.09 70.48M -0.65 0.00

In table 1 we can see Dicerna Pharmaceuticals Inc. and Rigel Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows Dicerna Pharmaceuticals Inc. and Rigel Pharmaceuticals Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Dicerna Pharmaceuticals Inc. -1,346.60% -90.8% -74.4%
Rigel Pharmaceuticals Inc. -158.35% -91.8% -77.5%

Risk and Volatility

Dicerna Pharmaceuticals Inc.’s current beta is 2.39 and it happens to be 139.00% more volatile than Standard and Poor’s 500. Rigel Pharmaceuticals Inc.’s 25.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 1.25 beta.

Liquidity

Dicerna Pharmaceuticals Inc. has a Current Ratio of 6.3 and a Quick Ratio of 6.3. Competitively, Rigel Pharmaceuticals Inc.’s Current Ratio is 6.1 and has 6.1 Quick Ratio. Dicerna Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Rigel Pharmaceuticals Inc.

Analyst Recommendations

Recommendations and Ratings for Dicerna Pharmaceuticals Inc. and Rigel Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Dicerna Pharmaceuticals Inc. 0 0 7 3.00
Rigel Pharmaceuticals Inc. 0 0 3 3.00

Dicerna Pharmaceuticals Inc. has a 90.32% upside potential and an average price target of $24.57. On the other hand, Rigel Pharmaceuticals Inc.’s potential upside is 189.26% and its average price target is $7. Based on the analysts opinion we can conclude, Rigel Pharmaceuticals Inc. is looking more favorable than Dicerna Pharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both Dicerna Pharmaceuticals Inc. and Rigel Pharmaceuticals Inc. are owned by institutional investors at 99.3% and 98% respectively. Dicerna Pharmaceuticals Inc.’s share held by insiders are 9.16%. Insiders Competitively, held 0.1% of Rigel Pharmaceuticals Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dicerna Pharmaceuticals Inc. 19.55% 23.96% -14% -18.49% 0% 19.55%
Rigel Pharmaceuticals Inc. -6.36% 2.31% -21.63% -32% -40.27% -3.91%

For the past year Dicerna Pharmaceuticals Inc. has 19.55% stronger performance while Rigel Pharmaceuticals Inc. has -3.91% weaker performance.

Summary

On 6 of the 11 factors Rigel Pharmaceuticals Inc. beats Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.